NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--As part of approving the human testing of ADXS11-001— the lead agent for the treatment of cervix cancer of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company — the Drugs Controller General of India (DCGI) required that the agent be tested to assure its safety prior to use. Testing will be completed in ten days and patient dosing will begin.
